- Home
- NUVL vs DAR Comparison
NUVL vs DAR Comparison
Compare NUVL & DAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- DAR
- Stock Information
- Founded
- NUVL 2017
- DAR 1882
- Country
- NUVL United States
- DAR United States
- Employees
- NUVL N/A
- DAR N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- DAR Packaged Foods
- Sector
- NUVL Health Care
- DAR Consumer Staples
- Exchange
- NUVL Nasdaq
- DAR Nasdaq
- Market Cap
- NUVL 4.9B
- DAR 5.8B
- IPO Year
- NUVL 2021
- DAR 1994
- Fundamental
- Price
- NUVL $87.24
- DAR $43.10
- Analyst Decision
- NUVL Strong Buy
- DAR Strong Buy
- Analyst Count
- NUVL 10
- DAR 10
- Target Price
- NUVL $112.60
- DAR $52.80
- AVG Volume (30 Days)
- NUVL 492.9K
- DAR 2.2M
- Earning Date
- NUVL 11-12-2024
- DAR 10-24-2024
- Dividend Yield
- NUVL N/A
- DAR N/A
- EPS Growth
- NUVL N/A
- DAR N/A
- EPS
- NUVL N/A
- DAR 1.62
- Revenue
- NUVL N/A
- DAR $5,911,565,000.00
- Revenue This Year
- NUVL N/A
- DAR N/A
- Revenue Next Year
- NUVL N/A
- DAR $4.77
- P/E Ratio
- NUVL N/A
- DAR $25.47
- Revenue Growth
- NUVL N/A
- DAR N/A
- 52 Week Low
- NUVL $56.52
- DAR $32.67
- 52 Week High
- NUVL $113.51
- DAR $51.36
- Technical
- Relative Strength Index (RSI)
- NUVL 38.02
- DAR 61.30
- Support Level
- NUVL $89.62
- DAR $40.99
- Resistance Level
- NUVL $96.24
- DAR $42.91
- Average True Range (ATR)
- NUVL 2.90
- DAR 1.41
- MACD
- NUVL -0.27
- DAR 0.15
- Stochastic Oscillator
- NUVL 15.96
- DAR 76.31
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About DAR Darling Ingredients Inc.
Darling Ingredients Inc develops and manufactures sustainable ingredients for customers in the pharmaceutical, food, pet food, fuel, and fertilizer industries. It collects and transforms all aspects of animal by-product streams into ingredients, including gelatin, fats, proteins, pet food ingredients, fertilizers. Also, the company recovers and converts used cooking oil and bakery remnants into feed and fuel ingredients. Darling has three primary business segments which are feed ingredients contributing the majority of revenue, food ingredients, and fuel ingredients. It provides grease trap services for food businesses and sells various equipment for collecting and delivering cooking oil. The company derives the majority of its revenue from customers in North America.